The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

SURMOUNT-OSA Study 1 recruited patients with OSA who were ... 2 involved patients who needed PAP therapy and in this group tirzepatide achieved an average AHI reduction of 30.4 events per hour ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Researchers found that women with hypertension who followed a very low-calorie ketogenic diet had lower systolic and diastolic blood pressure at 6 months than those who participated in intermittent ...

approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate ...

and FEV 1 /FVC ratio did not differ between the two groups. Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia (p < 0.0001), while BMI (p = 0.051) and %VC (p ...

New study shows tirzepatide reduces LV mass and heart fat in obesity-related HFpEF, potentially improving heart failure outcomes.